Adenoviral Delivery of Osteoprotegerin Ameliorates Bone Resorption in a Mouse Ovariectomy Model of Osteoporosis
Open Access
- 1 February 2001
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 3 (2) , 197-205
- https://doi.org/10.1006/mthe.2001.0245
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Effect of First Treatment with Aminobisphosphonates Pamidronate and Ibandronate on Circulating Lymphocyte SubpopulationsJournal of Bone and Mineral Research, 2000
- The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone ResorptionJournal of Bone and Mineral Research, 2000
- The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature OsteoclastsThe Journal of cell biology, 1999
- Clinical Effects of Raloxifene Hydrochloride in WomenAnnals of Internal Medicine, 1999
- Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and ActivationCell, 1998
- Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKLProceedings of the National Academy of Sciences, 1998
- Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanism by which OPG/OCIF Inhibits Osteoclastogenesisin Vitro1Endocrinology, 1998
- Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone DensityCell, 1997
- Perspectives: How many women have osteoporosis now?Journal of Bone and Mineral Research, 1995
- PamidronateDrugs, 1991